DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20193173

Cost analysis of various topical eye preparations currently available in Indian market

Shweta Agrawal, Neelesh Arya, Mehul Agrawal

Abstract


Background: topical eye preparations are very commonly used in India for different eye diseases hence their prices should not be much different in Indian pharmaceutical industry. The common man therefore has to shell out more money with medicine prices spinning out of his reach. Aim of this study was to compare the cost of drugs of the different brand of topical ophthalmic drugs.

Methods: cost of various topical eye preparations was compared using “Current Index of Medical Specialties” (CIMS) January-April 2019 and cost variation was recorded. Drugs were categorized into anti-infective and antiseptics, topical corticosteroids, mydriatics, anti-glaucoma drugs, anti-inflammatory and lubricants.

Results: That of the 26 drug formulations studied, the percentage cost variation of 10 drug formulations was more than 100%, out of which one formulation of moxifloxacin had more than 1000% variation. Cost ratio of 10 drug formulations were more than two. Moxifloxacin 0.5% eye drops had maximum percentage cost variation of 5610.66% and cost ratio of 57.11, followed by ofloxacin 0.30% eye drops (310.92%, 4.11), timolol 0.50% eye drops (263.64%, 3.64), ciprofloxacin 0.30% eye drops (142.42%, 2.42), tobramycin 0.30% eye drops (120.14%, 2.20).

Conclusions: There is a significant variation in the price of various topical eye preparations. As most of the preparations being prescribed on an out-patient basis, which was not covered under most of the insurance program. Out of pocket expenditure adversely affects the drug compliance in the long run. There should be a comprehensive action from policymakers, regulatory authorities, government agencies, doctors, pharmacists, and the general public to solve this issue of cost variation of drugs.


Keywords


Cost analysis, Cost variation, Eye drops, Pharmacoeconomics

Full Text:

PDF

References


Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Ind J Pharm Sci. 2007;69(1):160-3.

Patel D, Thiyagu R, Surulivelrajan M, Patel H, Pandey S. Price variability among the oral antibiotics available in a South Indian Tertiary Care Hospital. J Clin Diagn Res. 2009;3(6):1871-5.

Shankar PR, Subish P, Mishra P, Lalit M. Ambiguous pricing of Nepalese medicines. J Inst Med. 2006;28(3):35-8.

Nagaich U. Recent advances in ocular drug delivery system. J Adv Pharm Technol Res. 2014;5(4):151.

Rawas-Qalaji M, Williams CA. Advances in ocular drug delivery. Curr Eye Res. 2012;37(5):345-56.

Mehani R, Sharma P. Cost variation analysis of oral anti-diabetic drugs. Int J Basic Clin Pharmacol. 2018 Sep;7(9):1709-14.

Kumar V, Gupta NV, Kumar KA. A comparison between old and latest systems in DPCO. Int J Pharm Pharmaceut Sci. 2014;6(2):19-20.

Compendium of notified ceiling prices of scheduled drugs- NPPA; 2015. Available at: http://www.nppaindia.nic.in/ceiling price. Accessed 12 Aug 2018.

Jana S, Mondal P. Pharmacoeconomics: The need to sensitize undergraduate medical students. Indian Pharmacol. 2005;37(5):277-8.

Muir KW, Lee PP. Glaucoma Medication Adherence: Room for Improvement in Both Performance and Measurement. Arch Ophthalmol. 2011;129(2):243-5.

Brown MT, Bussell JK. Medication Adherence: WHO Cares? Mayo Clin Proc. 2011;86(4):304-14.

Chandrappa S, Rajarathna K. Cost variation analysis of various brands of topical eye preparations currently available in Indian pharmaceutical market. Int J Basic Clin Pharmacol. 2018;7:2364-7.

Jadhao T, Advani M, Jamdade S. Cost variation analysis of antiglaucoma drugs available in Indian market. Paripex Ind J Res. 2018 Feb 14;6(2).

Sohn HS, Kwon J, Park E. Out-of-Pocket (OOP) Expenditure for Prescription Drugs among South Korean Outpatients under the National Health Insurance System: Focus on Chronic Diseases Including Diabetes. J Diabetes Metab. 2012;3(5):197.

Tiwari A, Reddy P, Goyal C. Cost analysis of antifungal drugs available in India: A pharmacoeconomic perspective. Indian J Pharmacy Pharmacol. 2016;3(4):192-6.